BMY-25801, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]2-(1-methyl-2-oxopropoxy )
benzamide, a new
antiemetic agent free of D2-dopamine receptor antagonist properties, was effective against
emesis induced by
cytostatic agents (
cisplatin,
cyclophosphamide and
doxorubicin) and total body radiation in the ferret. It also was effective against
cisplatin-induced
emesis in the dog; however, it was inactive against
emesis caused by
apomorphine and
hydergine in the same species. In terms of activity profile,
BMY-25801 could be differentiated both from
metoclopramide and
domperidone.
Metoclopramide was nonselectively active against
emesis induced by
cytostatic agents, radiation and D2-dopamine receptor agonists, whereas
domperidone was selectively effective against
emesis induced by
apomorphine and
hydergine only.
BMY-25801 failed to reveal any D2-dopamine receptor antagonist properties in several pharmacological tests (
catalepsy,
apomorphine stereotypy, serum
prolactin, striatal dihydroxyphenylacetic
acid and [3H]
spiperone displacement) whereas
metoclopramide was uniformly active in these tests. The activity profile of
domperidone was compatible with its classification as a peripherally acting D2-dopamine receptor antagonist.
BMY-25801 and
metoclopramide antagonized
serotonin-induced
bradycardia (Bezold-Jarisch reflex) in the anesthetized rat, a response involving peripheral neuronal 5-HT3 receptors. Thus,
BMY-25801 represents a novel
antiemetic acting independently of D2-dopamine receptor mechanisms; however, its exact mode of action remains unknown.